Home > Media KIt > News Room

Morepen Laboratories Limited
Unaudited Financial Results
For the Quarter ended 30th June, 2012
            (Rs. in Lacs)
      Quarter ended    Year ended
  30.06.2012 31.03.2012 30.06.2011   31.03.2012
  (Unaudited)   (Audited)
1(a) Net Sales/Income from Operations (Net of Excise Duty)   7650 7460 5927   26117
(b) Other Operating Income   157 226 96   833
  Total Income from Operations (Net)    7807 7686 6023   26950
2 Expenditure            
  a)  Cost of Material Consumed   3436 3480 3676   13242
  b)  Purchase of stock - in - trade   1326 1769 721   5041
  c)  Changes in inventories of  Finished goods, Work -in- progress and Stock-in-trade    98 (297) (138)   (507)
  d)  Employee benefits expenses   849 865 769   3265
  e) Depreciation and Amortisation   1135 1193 1141   4689
  f) Power and Fuel   275 245 232   982
  g) Travelling Expenses   133 146 149   595
  h) Selling and Distribution Expenses   290 384 173   1050
  i)  Other Expenses   473 335 390   1518
  Total Expenditure   8015 8120 7113   29875
3 Profit / (Loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)   (208) (434) (1090)   (2925)
4 Other Income  - 1 101 -   101
5 Profit / (Loss)  from Ordinary activities before Finance Cost and Exceptional Items (3+4)   (207) (333) (1090)   (2824)
6 Finance Cost   224 147 223   796
7 Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)   (431) (480) (1313)   (3620)
8 Exceptional Items - Income/(Expense)   - - -   -
9 Profit / (Loss) from Ordinary Activities before Tax (7-8)   (431) (480) (1313)   (3620)
10 Tax Expense    - - -   -
11 Profit / (Loss) from Ordinary Activities after Tax (9-10)   (431) (480) (1313)   (3620)
12 Extraordinary Items-Income/(Expense)   - 1204 -   1204
13 Net Profit /(Loss) for the period  (11+12)   (431) 724 (1313)   (2416)
14 Paid-up Equity Share Capital of Face Value of Rs.2/- each   8996 8996 8996   8996
15 Reserves excluding Revaluation reserves   - - -   14349
16 a) Earning Per Share before Extraordinary Items (in Rs.)            
  - Basic & Diluted   (0.10) (0.11) (0.29)   (0.82)
  b) Earning Per Share after Extraordinary Items (in Rs.)            
  - Basic & Diluted   (0.10) 0.16 (0.29)   (0.55)
A PARTICULARS OF SHAREHOLDING            
1 Public Shareholding            
  - Number of Shares   294454615 294454615 294454615   294454615
  - Percentage of shareholding   65.46% 65.46% 65.46%   65.46%
2 Promoters and Promoter Group Shareholding            
  a) Pledged / Encumbered            
  - Number of Shares   610000 610000 610000   610000
  - Percentage of shares (as a % of the total shareholding of promoters and promoter group)   0.39% 0.39% 0.39%   0.39%
  - Percentage of shares (as a % of the total share capital of the company)   0.14% 0.14% 0.14%   0.14%
  b) Non-encumbered            
   - Number of Shares   154761588 154761588 154761588   154761588
  - Percentage of shares (as a % of the total shareholding of promoters and promoter group)   99.61% 99.61% 99.61%   99.61%
  - Percentage of shares (as a % of the total share capital of the company)   34.40% 34.40% 34.40%   34.40%
B INVESTORS COMPLAINTS   For the Quarter ended 30th June, 2012
  Pending at the beginning of the quarter   Nil
  Received during the quarter   4
  Disposed off during the quarter   4
  Remaining unresolved during the quarter   Nil
Notes:              
1. The above results were reviewed by the audit committee and have been approved by the Board of Directors in the meeting held on 6th August, 2012. A limited review of the same had been carried out by the statutory auditors.
2. The Company is exclusively engaged in the Pharmaceutical Business segment.
3. Consolidated Income from Operatitons, Net Profit/ (Loss) and EPS for the quarter ended 30th June, 2012 stands at Rs. 8235 Lacs,  Rs.(418) Lacs & Rs. (-) 0.10 respectively.  
 
4. The figures of the previous quarter/year have been re-grouped/re-classified to conform to the current quarter classification.
 
        For and on behalf of the Board
                 
                 
                 
Place: New Delhi         (Sushil Suri)
Date: 06.08.2012 Chairman & Managing Director